




12-27-2001

ET

Docket No.:

539.177.11

12-18-2001



Y

D

U.S. Patent & TMO/TM Mail Rpt Dt. #22

To Commissioner of Pat.

101925493

attached original documents or copy thereof

1. Name of conveying party(ies):

Restoragen, Inc. f/k/a BioNebraska, Inc.

- Individual(s) Association
General Partnership Limited Partnership
Corporation-State Delaware
Other

Additional names(s) of conveying party(ies) Yes No

3. Nature of conveyance:

- Assignment Merger
Security Agreement Change of Name
Other

Execution Date: December 18, 2001

2. Name and address of receiving party(ies):

Name: Medtronic International, Ltd.

Internal Address: World Headquarters

Street Address: 710 Medtronic Parkway

City: Minneapolis State: MN ZIP: 55432

- Individual(s) citizenship
Association
General Partnership
Limited Partnership
Corporation-State Delaware
Other

If assignee is not domiciled in the United States, a domestic designation is Yes No
(Designations must be a separate document from Additional name(s) & address(es) Yes No

4. Application number(s) or registration numbers(s):

A. Trademark Application No.(s)

Please see attached list

B. Trademark Registration No.(s)

Please see attached list

Additional numbers Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: David C. West, Fredrikson & Byron, P.A.

Internal Address:

Street Address: 1100 International Centre

900 Second Avenue South

City: Minneapolis State: MN ZIP: 55402

6. Total number of applications and registrations involved:

5

7. Total fee (37 CFR 3.41): \$ 140.00

- Enclosed
Authorized to be charged to deposit account

8. Deposit account number:

06-1910

12/26/2001 DBYRNE 00000113 78072224
01 FC:481 40.00 DP
02 FC:482 100.00 DP

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

David C. West

Name of Person Signing

David West

Signature

12/18/01

Date

Total number of pages including cover sheet, attachments, and

TRADE MARK

**ATTACHMENT TO RECORDATION FORM COVER SHEET**

**Box 4B Registered Trademark**

Reg. No. 1,666,349 BIMELYZE, registered December 3, 1991

**Box 4A Trademark Application Numbers**

Serial No. 78-072-224, BETATROPIN, filed July 3, 2001

Serial No. 78-072-224, RESTORAGEN, filed May 11, 2001

Serial No. 75-770-718, MACRO PHARMACEUTICALS, filed July 12, 1999

Serial No. 75-770-719, MACRO PHARMA, filed July 12, 1999

::ODMA\PCDOCS\FBDOCS1\2593454\1

# SECURITY AGREEMENT

DATE: December 18, 2001

DEBTOR: Restoragen, Inc. Tax I.D. # 47-0727668  
4130 N.W. 37<sup>th</sup> Street Organization I.D. # 0002339166  
Lincoln, Nebraska 68524-1637

SECURED PARTY: Medtronic International, Ltd., as Agent  
World Headquarters  
710 Medtronic Parkway, N.E.  
Minneapolis, MN 55432-5604

1. Security Interest and Collateral. To secure the payment of outstanding principal and interest on that certain \$10,000,000 Secured Convertible Promissory Note of even date herewith made by Debtor to Medtronic International, Ltd. ("Medtronic") and each other Secured Convertible Promissory Note made by Debtor pursuant to that certain Bridge Loan Agreement dated December \_\_, 2001 by and among Debtor, Medtronic and the other lenders named therein (the "Loan Agreement") (individually a "Note", collectively the "Notes") and the performance of every liability and obligation of every type and description that Debtor may now or at any time hereafter owe to any Secured Party pursuant to the Loan Agreement or pursuant to this Agreement, whether such debt, liability or obligation now exists or is hereafter created or incurred, and whether it is absolute or contingent, liquidated or unliquidated, or sole, joint, several or joint and several (all such debts, liabilities and obligations and any amendments, extensions, renewals or replacements thereof collectively referred to herein as the "Obligations"), Debtor hereby grants Medtronic, as agent for itself and for the lenders who are parties to the Loan Agreement (each such lender a "Secured Party"; Medtronic and all such lenders the "Secured Parties"), a first priority security interest (the "Security Interest") in all the following property of Debtor (the "Collateral"):

- A. Certain Accounts and Rights to Payment: Each and every right of Debtor to the payment of money arising out of the grant of any license rights in any of Debtor's intellectual property or other general intangibles, whether such right to payment now exists or hereafter arises, whether such right to payment is or is not already earned by performance, and howsoever such right to payment may be evidenced, together with all other rights and interests (including all liens and security interests) which Debtor may at any time have by law or agreement against any such licensee ("License Receivables"); and
- B. General Intangibles: All general intangibles of Debtor, whether now owned or hereafter acquired, including, but not limited to, applications for patents (including, but not limited to, those listed on Schedule 1 hereto), patents (including, but not limited to, those listed on Schedule 1 hereto), copyrights, trademarks (including, but not limited to, those listed on Schedule 2 hereto), trade

secrets, good will, tradenames, all licenses of any of the foregoing, customer lists, permits and franchises, software, and the right to use Debtor's name, and any and all membership interests, governance rights, and financial rights in each and every limited liability company, and all payment intangibles and all other General Intangibles of the Debtor, as such term may be defined in the UCC;

together with all substitutions and replacements for and products of any of the foregoing property and proceeds of any and all of the foregoing property together with all books and records of Debtor related to the Collateral.

2. Representations, Warranties and Agreements. Debtor represents, warrants and agrees that:

2.1. Debtor is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware, and the state of Delaware has been Debtor's state of organization since before July 1, 2001. Debtor has full power and authority to execute this Agreement, to perform Debtor's obligations hereunder and to subject the Collateral to the Security Interest. Debtor's taxpayer identification number is the number shown at the beginning of this Agreement. Debtor's organizational identification number is the number shown at the beginning of this Agreement.

2.2. Debtor's chief place of business is located at the address shown at the beginning of this Agreement. Debtor's records concerning its License Receivables and general intangibles are kept at such address. Debtor will give at least 30 days' advance written notice to Secured Party of any change in Debtor's jurisdiction of organization or chief place of business and any change in or addition of any Collateral location. Debtor will take all such actions as Medtronic may reasonably request to permit Medtronic to establish and perfect the Security Interest in all jurisdictions Medtronic deems necessary, including but not limited to the execution, delivery or endorsement of any and all instruments, documents, assignments, security agreements and other agreements and writings that Medtronic may at any time reasonably request in order to secure, protect, perfect or enforce the Security Interest and any Secured Party's rights under this Agreement.

2.3. Debtor has (or will have at the time Debtor acquires rights in Collateral hereafter arising) absolute title to each item of Collateral free and clear of all security interests, liens and encumbrances. Debtor will keep all Collateral free and clear of all security interests, liens and encumbrances except the Security Interest, and will defend the Collateral against all claims or demands of all persons other than the Secured Parties; provided that Debtor may grant a second priority security interest in the Collateral in connection with up to \$20,000,000 of additional debt financing if and only if such additional secured parties enter into an appropriate intercreditor subordination agreement with Medtronic that gives Medtronic, as agent for the Secured Parties, control over all actions regarding foreclosure on the Collateral. Debtor will promptly pay or properly and timely contest all taxes and other governmental charges levied or assessed upon or

against any Collateral or upon or against the creation, perfection or continuance of the Security Interest.

2.4. Until the Obligations are satisfied in full, Debtor will not, without Medtronic's prior written consent, sell any of the Collateral or enter into any agreement that is inconsistent with any Secured Party's rights under this Agreement, except that Debtor may grant licenses to and enter into collaborative arrangements with respect to the Collateral in the ordinary course of business so long as such agreements are not inconsistent with any Secured Party's rights under the Loan Agreement or this Agreement. Debtor further agrees that it will not take any action, or permit any action to be taken by others under its control, or fail to take any action, that would affect the validity of the Collateral or enforcement of any Secured Party's rights in the Collateral.

2.5. This Agreement has been duly and validly authorized by all necessary action by Debtor.

2.6. Debtor will at all reasonable times and with reasonable notice permit Medtronic or its representatives to examine or inspect any Collateral, wherever located, and to examine, inspect and copy Debtor's books and records pertaining to the Collateral and its business and financial condition. In the case of an Event of Default or if in connection with Medtronic's evaluation of the Collateral pursuant to Section 1 of this Agreement, Medtronic reasonably deems itself to be inadequately secured, and provided that Medtronic keeps such information confidential, Medtronic may send and discuss with licensees of Debtor's intellectual property requests for verifications of amounts owed to Debtor.

2.7. If Medtronic at any time so requests after the occurrence of an Event of Default, Debtor will promptly transfer to Medtronic any instrument, document, chattel paper, or investment properties constituting the Collateral, duly endorsed or assigned by Debtor.

2.8. Debtor will keep accurate and complete records pertaining to the Collateral and pertaining to Debtor's business and financial condition and submit to Medtronic such periodic reports concerning the Collateral and Debtor's business and financial condition as Medtronic may from time to time reasonably request.

2.9. Debtor will pay when due or reimburse each Secured Party on demand for all costs of collection of any of the Obligations and all other out-of-pocket expenses (including all reasonable attorneys' fees) incurred by such Secured Party in connection with the satisfaction, protection, defense or enforcement of the Security Interest or the protection, defense or enforcement of this Agreement or any or all of the Obligations, including expenses incurred in any litigation or bankruptcy or insolvency proceedings.

2.10. The Obligations have been incurred and the Collateral will be used primarily for business purposes.

2.11. All License Receivables are (or will be when arising) the valid, genuine and legally enforceable obligation, subject to no defense, set-off or counterclaim (other than those arising in the ordinary course of business) of each licensee named therein or in Debtor's records pertaining thereto as being obligated to pay such obligation. Debtor will not subordinate any License Receivable to claims of other creditors of such licensee.

2.12. Debtor will promptly notify Secured Party of any material loss of or damage to any Collateral or of any adverse change in the prospect of payment of any material sums due under any license constituting Collateral.

2.13. Debtor will from time to time execute such financing statements as Medtronic may reasonably deem required to be filed in order to perfect the Security Interest and, if any Collateral is covered by a certificate of title, execute such documents as may be required to have the Security Interest properly noted on a certificate of title. In addition, Debtor authorizes Medtronic to file any financing statement Medtronic deems necessary.

2.14. Debtor will not use or keep any Collateral, or permit it to be used or kept, for any unlawful purpose or in violation of any federal, state or local law, statute or ordinance.

2.15. If Debtor at any time fails to perform or observe any agreement contained in this Section 2, and if such failure shall continue for a period of 30 calendar days after Medtronic gives Debtor written notice thereof, Medtronic may (but need not) perform or observe such agreement on behalf and in the name, place and stead of Debtor (or, at Medtronic's option, in Medtronic's own name) and may (but need not) take any and all other actions that Medtronic may reasonably deem necessary to cure or correct such failure. Debtor shall pay Medtronic on demand the amount of all monies expended and all costs and expenses (including reasonable attorneys' fees) incurred by Medtronic in connection with or as a result of Medtronic's performing or observing such agreements or taking such actions, together with interest thereon from the date expended or incurred by Medtronic at the highest rate then applicable to any of the Obligations. To facilitate the performance or observance by Medtronic of such agreements of Debtor (in the event Debtor does not cure any such failure during the above-described 30-day period), Debtor hereby irrevocably appoints (which appointment is coupled with an interest) Medtronic, or its delegate, as the attorney-in-fact of Debtor with the right (but not the duty) from time to time to create, prepare, complete, execute, deliver, endorse or file, in the name and on behalf of Debtor, any and all instruments, documents, financing statements, and other agreements and writings required to be obtained, executed, delivered or endorsed by Debtor under this Section 2.

3. Account Verification and Collection Rights of Medtronic. Following an Event of Default, Medtronic shall have the right to verify any License Receivables in the name of Debtor or in Medtronic's own name; and Debtor, whenever requested pursuant to the terms of this Section, shall furnish Medtronic with duplicate statements of the License Receivables, which statements may be mailed or delivered by Medtronic for that purpose. Medtronic may, at any

time after the occurrence of an Event of Default, notify any License Receivable debtor that such right to payment has been assigned or transferred to Medtronic for security and shall be paid directly to Medtronic as agent for the Secured Parties. If Medtronic so requests, at any time after the occurrence of an Event of Default, Debtor will so notify such License Receivable debtors in writing and will indicate on all invoices to such License Receivable debtors that the amount due is payable directly to Medtronic as agent for the Secured Parties. At any time after Medtronic or Debtor gives such notice to a License Receivable debtor, Medtronic may (but need not), on behalf of the Secured Parties or in Debtor's name, demand, sue for, collect or receive any money or property at any time payable or receivable on account of, or securing, any such License Receivable, or grant any extension to, make any compromise or settlement with or otherwise agree to waive, modify, amend or change the obligations (including collateral obligations) of any such License Receivable debtor.

4. Events of Default. The occurrence of any of the following shall, at the option of the Medtronic, be an Event of Default:

A. Any "Event of Default" (as defined in such agreement) by Debtor under any note or any other agreement evidencing the Obligations;

B. Debtor's failure to comply with any representation, warranty or covenant hereunder if not cured within thirty (30) days after written notice;

C. Transfer or disposition of any of the Collateral, except as permitted by this Agreement; or

D. Attachment, execution or levy on any of the Collateral.

5. Remedies upon Event of Default. Upon the occurrence of an Event of Default and at any time thereafter, Medtronic, on behalf of all the Secured Parties, may exercise any one or more of the following rights and remedies:

5.1. declare all Obligations to be immediately due and payable, which shall then be immediately due and payable, without presentment or other notice or demand;

5.2. exercise and enforce any or all rights and remedies available upon default to a secured party under the Uniform Commercial Code, including but not limited to the right to take possession of any Collateral, proceeding without judicial process if permitted by law or by judicial process, and the right to use, sell, lease or otherwise dispose of any or all of the Collateral, and in connection therewith, Medtronic may require Debtor to make the Collateral available to Medtronic at a place to be designated by Medtronic that is reasonably convenient to both parties, and if notice to Debtor of any intended disposition of Collateral or any other intended action is required by law in a particular instance, such notice shall be deemed commercially reasonable if given (in the manner specified in Section 8.2) at least 10 business days prior to the date of intended disposition or other action; or

5.3. exercise or enforce any or all other rights or remedies available to Medtronic by law or agreement against the Collateral, including specifically the right to use the Collateral, against Debtor or against any other person or property.

All rights and remedies of the Secured Parties shall be cumulative and may be exercised singularly or concurrently, at Medtronic's option, and the exercise or enforcement of any one such right or remedy shall neither be a condition to nor bar the exercise or enforcement of any other.

6. Other Personal Property. Unless at the time Medtronic takes possession of any tangible Collateral, or within seven days thereafter, Debtor gives written notice to Medtronic of the existence of any goods, papers or other property of Debtor, not affixed to or constituting a part of such Collateral, but which are located or found upon or within such Collateral, neither Medtronic nor any other Secured Party shall be responsible or liable to Debtor for any action taken or omitted by or on behalf of Medtronic or any other Secured Party with respect to such property without actual knowledge of the existence of any such property or without actual knowledge that it was located or to be found upon or within such Collateral.

7. Termination of Security Interest; Release of Collateral. When all outstanding Obligations have been irrevocably paid in full, the Security Interest shall terminate and all rights to each item of Collateral shall revert to the Debtor. At any time before the Security Interest terminates pursuant to Section 7, Medtronic may, at the written request of the Debtor, release any of the Collateral (but not all or substantially all the Collateral). Upon any such termination of the Security Interest or release of Collateral, Medtronic will, at the expense of the Debtor, execute and deliver to Debtor such documents as Debtor shall reasonably request to evidence the termination of the Security Interest or the release of such Collateral, as the case may be.

8. Miscellaneous.

8.1. This Agreement can be waived, modified, amended, terminated or discharged, and the Security Interest can be released, only explicitly in a writing signed by Medtronic. A waiver signed by Medtronic shall be effective only in the specific instance and for the specific purpose given. Mere delay or failure to act shall not preclude the exercise or enforcement of Medtronic's or any other Secured Party's rights or remedies.

8.2. All notices to be given to Debtor shall be deemed sufficiently given if delivered or mailed by registered or certified mail, postage prepaid, to Debtor at its address set forth above or at such other address as Debtor may subsequently provide to Medtronic.

8.3. Any Secured Party's duty of care with respect to Collateral in its possession (as imposed by law) shall be deemed fulfilled if such Secured Party exercises reasonable care in physically safekeeping such Collateral or, in the case of Collateral in the custody or possession of a bailee or other third person, exercises reasonable care in the selection of the bailee or other third person, and such Secured Party need not otherwise preserve, protect, insure or care for any Collateral. Neither Medtronic nor any other Secured Party shall be obligated to preserve any rights Debtor may have against prior parties, to realize on the



Collateral at all or in any particular manner or order, or to apply any cash proceeds of Collateral in any particular order of application.

8.4. This Agreement shall be binding upon and inure to the benefit of Debtor and the Secured Parties and their respective successors and assigns and shall take effect when signed by Debtor and delivered to Medtronic, and Debtor waives notice of Medtronic's or any other Secured Party's acceptance hereof. Except for an assignment to SMS Securities Sigg Merkli Schroedel AG or its affiliates, or to a successor to substantially all of Medtronic's business and assets to which this Agreement relates, Medtronic will not assign its rights under this Agreement without the Company's consent, which shall not be unreasonably withheld.


8.5. A carbon, photographic or other reproduction of this Agreement or of any financing statement signed by Debtor shall have the same force and effects as the original for all purposes of a financing statement.

8.6. This Agreement shall be governed by the internal laws of the State of Delaware. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby.

8.7. All representations and warranties contained in this Agreement shall survive the execution, delivery and performance of this Agreement and the creation and payment of the Obligations.

ACCORDINGLY, this Security Agreement has been duly executed by the parties as of the date first set forth above.

RESTORAGEN, INC.

By:   
Its: Senior VP & CFO

MEDTRONIC INTERNATIONAL, LTD.

By: \_\_\_\_\_  
Its: \_\_\_\_\_

Collateral in all or in any particular manner or order, or to apply any cash proceeds of Collateral in any particular order of application.

8.4. This Agreement shall be binding upon and inure to the benefit of Debtor and the Secured Parties and their respective successors and assigns and shall take effect when signed by Debtor and delivered to Medtronic, and Debtor waives notice of Medtronic's or any other Secured Party's acceptance hereof. Except for an assignment to SMS Securities Sigg Merkli Schroedel AG or its affiliates, or to a successor to substantially all of Medtronic's business and assets to which this Agreement relates, Medtronic will not assign its rights under this Agreement without the Company's consent, which shall not be unreasonably withheld.

8.5. A carbon, photographic or other reproduction of this Agreement or of any financing statement signed by Debtor shall have the same force and effects as the original for all purposes of a financing statement.

8.6. This Agreement shall be governed by the internal laws of the State of Delaware. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby.


8.7. All representations and warranties contained in this Agreement shall survive the execution, delivery and performance of this Agreement and the creation and payment of the Obligations.

ACCORDINGLY, this Security Agreement has been duly executed by the parties as of the date first set forth above.

RESTORAGEN, INC.

By: \_\_\_\_\_  
Its: \_\_\_\_\_

MEDTRONIC INTERNATIONAL, LTD.

By:   
Its: \_\_\_\_\_

SCHEDULE 1

Restoration Patents and Patent Applications

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
389		US	60/		CONLON			Antimicrobial Peptides from X. tropicalis				
332	PCT/US99/18575 8/13/99; 09/374,165 8/13/99; 09/503,340 2/14/00; 60/096,607 8/14/98	AU	55642/99		CONLON	2/5/2001		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING	9/14/2001	MEDICAL	Creighton University School of Medicine
330		CA	2338885		CONLON	8/13/1999		Antimicrobial Peptides Isolated From the Skin of American Frogs				
331	PCT/US99/18575 8/13/99; 09/374,165 8/13/99; 09/503,340 2/14/00; 60/096,607 8/14/98	EP	99942213.2		CONLON	3/12/2001		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING	8/14/2001	MEDICAL	Creighton University School of Medicine

TRADEMARK

REEL: 002413 FRAME: 0302

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
333	PCT/US99/18575 8/13/99; 09/374,165 8/13/99; 09/503,340 2/14/00; 60/096,607 8/14/98	JP	2000-565002	CONLON	2/14/2001		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING		MEDICAL	Creighton University School of Medicine
224	09/374,165 8/13/99; 09/503,340 2/14/00; 60/096,607 8/14/98	PCT	PCT/US99/1 8575	CONLON	8/13/1999		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING		MEDICAL	Creighton University School of Medicine
361	60/181,934 2/11/00	PCT	PCT/US01/0 4108	CONLON	2/9/2001		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING	9/11/2001	MEDICAL	Creighton University School of Medicine
227	PCT/US99/18575 8/12/99; 60/096,607 8/14/98; 60/ 2/11/00; 09/503,340 2/14/00;	US	09/374,165	CONLON	8/13/1999		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING		MEDICAL	Creighton University School of Medicine

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
256	09/374,165 8/13/99; PCT/US99/18575 8/13/99; 09/374,165 8/13/99; 60/096,607 8/14/98	US	09/503,340	CONLON	2/14/2000		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING		MEDICAL	Creighton University School of Medicine
342	60/181,934 2/11/00	US	09/779,833	CONLON	2/9/2001		Antimicrobial Peptides Isolated From the Skin of American Frogs	PENDING	7/3/2001	MEDICAL	Creighton University School of Medicine
307							Assessment of Genentech patents	PENDING			
326		US		COOLIDGE			Assessment: Rescue and Refurbishing of Pancreatic Beta Cells				
327		US		COOLIDGE			Assessment: GLP-1 As a Treatment for High Cholesterol and Alzheimer's Disease				
		US	60/032,928	FRANK	12/6/1996		Bioassay for Growth Hormone Releasing Hormone	CLOSED		ASSAY	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE	
219	60/032,928	US	08/986,049	6221617	FRANK	12/5/1997	4/24/2001	Bioassay for Growth	PENDING	10/24/2004	ASSAY	
320		US	08/294,434	5635371	GOZZI	8/23/1994	6/3/1997	Hormone Releasing Hormone Chemical Method for Selective Modification of the N- and/or C-Terminal amino acid .alpha.-carbon D reactive group of a recombinant polypeptide or a portion thereof	PATENTE	12/3/2004	PEPTIDE	BioNebraska
320	CON 07/912,798 7/13/92 (aban.); FWC 07/324,392 3/14/89 (aban.)	US	07/912,798		GOZZI	7/13/1992		Chemical Method for Selective Modification of the N- and/or C-Terminal amino acid .alpha.-carbon D reactive group of a recombinant polypeptide or a portion thereof				
	CONTAINED IN SAME FILE WITH 08/294,434 8/23/94 USP 5,635,371 issued 6/3/97; which is a CON of this abandoned file											

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
403	CIP 07/912,728 7/13/92 (aban.)	US	08/091,751	STOUT	7/13/1993		Chemical Method for Selective Modification of the N- and/or C-Terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof	ABANDONED		PEPTIDE	
334		US	08/457,166	STOUT	6/1/1995	8/12/1997	Chemical Method for Selective Modification of the N- and/or C-Terminal amino acid .alpha.-carbon reactive group of a recombinant polypeptide or a portion thereof				
186	CON 08/091,751 7/13/93 (aban.); CIP 07/912,728 7/13/92 (aban.)	AU	68675/98	XIA	3/21/1998		Chlorella Virus Promoters	PENDING	10/16/2001	PEPTIDE	BioNebraska
184		CA	2284104	XIA	3/21/1998		Chlorella Virus Promoters	PENDING	3/21/2002	PEPTIDE	
182		CN	98803491.3	XIA	3/21/1998		Chlorella Virus Promoters	PENDING	3/21/2002	PEPTIDE	
185		CZ	PV 1999-3334	XIA	9/20/1999		Chlorella Virus Promoters	PENDING		PEPTIDE	

TRADEMARK

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
181	PCT/US98/05655 3/21/98	EP	98914278.1	XIA	3/21/1998		Chlorella Virus Promoters	PENDING	3/31/2002	PEPTIDE	
189	PCT/US98/05655 3/21/98; 08/821,559 (9/28/00)	HU	P0001817	XIA	3/21/1998		Chlorella Virus Promoters	PENDING	3/28/2002		
187	PCT/US98/05655 3/21/98	JP	543277/1998	XIA	3/21/1998		Chlorella Virus Promoters	PENDING		PEPTIDE	
183	PCT/US98/05655 3/21/98	PCT	US98/05655	XIA	3/21/1998		Chlorella Virus Promoters	CLOSED			
188	PCT/US98/05655 3/21/98	PL	P-335862	XIA	3/21/1998		Chlorella Virus Promoters	PENDING		PEPTIDE	
108	PCT/US98/05655 3/21/98	SG	9904557-7	XIA	3/21/1998	11/21/2000	Chlorella Virus Promoters	PENDING	3/21/2002	PEPTIDE	
	DIV. -401 filed 7/9/01; CON	US	09/400,541	XIA	9/21/1999		Chlorella Virus Promoters				
	PCT/US98/05655 3/21/98; CIP 08/821,559 3/21/97 (5,846,774)	US	09/400,541	XIA	9/21/1999		Chlorella Virus Promoters				
299	PCT/US98/05655 3/21/98; CIP 08/821,559 3/21/97 (5,846,774)	US	09/403,675	XIA	8/11/1999		Chlorella Virus Promoters	ABANDONED		PEPTIDE	
		US	08/821,559	XIA	3/21/1997	12/8/1998	Chlorella Virus Promoters	PATENTE D	6/8/2002	PEPTIDE	BioNebraska



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
401	DIV 09/400,541 9/21/99; PCT/US98/05655 3/21/98; CIP 08/821,559 3/21/97 (5,846,774)	US		XIA	7/9/2001		Chlorella Virus Promoters	PENDING	8/8/2001	PEPTIDE	
160		CA	2174525	2174525 WAGNER BREDDAM	10/28/1994		Clostrapain Customized Proteases with Altered Transacylation Activity	PENDING	10/28/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
159		EP	95921432.1	BREDDAM	10/28/1994		Customized Proteases with Altered Transacylation Activity	PENDING	9/22/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
158		JP	517672/1995	BREDDAM	10/28/1994		Customized Proteases with Altered Transacylation Activity	PENDING	10/28/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
161		NZ	283995	BREDDAM	10/28/1994		Customized Proteases with Altered Transacylation Activity	PENDING		PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
	08/329,892 10/27/94; 08/144,704 10/28/93;	PCT	PCT/US95/0 6682	WO 95/20039 BREDDAM	10/28/1994	7/27/1995	Customized Proteases with Altered Transacylation Activity	CLOSED		PEPTIDE	Carlsberg Laboratory A/S - 7/92 license

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
156	CON 08/329,892 10/27/94; CIP 08/144,704 10/28/93 (aban.)	US	08/899,324	5945329	BREDDAM	7/23/1997	8/31/1999	Customized Proteases with Altered Transacylation Activity	PATENTE D	2/28/2003	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
157		US	08/329,892	6187579	BREDDAM	10/27/1994	2/13/2001	Customized Proteases with Altered Transacylation Activity	PENDING		PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
206		AU	26513/95	679861	BREDDAM	10/28/1994		Customized Proteases with Altered Transacylation Activity	GRANTED		PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
375	PCT/US95/06682	PCT	PCT/EP01/02 882		GOKE	3/14/2001		Effects of Glucagon-like Peptide-1(7- 36)amide on Antro-Pyloro- Duodenal Motility in the Interdigestive State and with Duodenal Lipid Perfusion in Humans		7/11/2001	MEDICAL	
6374	60/189,091 3/14/00	US	09/805,507		GOKE	3/14/2001		Effects of Glucagon-like Peptide-1(7- 36)amide on Antro-Pyloro- Duodenal Motility in the Interdigestive			MEDICAL	

TRADEMARK

F&L NO.	RELATED APPLN. NO.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
290		US	60/189,091	GOKE	3/14/2000		State and with Duodenal Lipid Perfusion in Humans				
							Effects of Glucagon-like Peptide-1(7- 36)amide on Antro-Pyloro- Duodenal Motility in the Interdigestive State and with Duodenal Lipid Perfusion in Humans	PENDING		MEDICAL	
357	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	AU	13423/00	DORMADY	3/6/2001		Enzymatic Amidation of Peptides	PENDING	2/28/2002	PEPTIDE	
358	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	CA		DORMADY	5/2/2001		Enzymatic Amidation of Peptides	PENDING	5/2/2002	PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
359	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	CN	99812904.6	DORMADY	4/30/2001		Enzymatic Amidation of Peptides	PENDING	8/6/2001	PEPTIDE	
360	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	CZ		DORMADY			Enzymatic Amidation of Peptides	PENDING	7/16/2001	PEPTIDE	
356	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	EP	99956920.5	DORMADY	5/23/2001		Enzymatic Amidation of Peptides	PENDING		PEPTIDE	
347	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	HU		DORMADY	5/4/2001		Enzymatic Amidation of Peptides	PENDING		PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
348	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	IL	142617		DORMADY	4/16/2001		Enzymatic Amidation of Peptides	PENDING	10/16/2004	PEPTIDE	
349	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	IN	IN/PCT/2001/ 00198/DEL		DORMADY	3/7/2001		Enzymatic Amidation of Peptides	PENDING	7/7/2001	PEPTIDE	
350	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	IS	5932/2001		DORMADY	5/2/2001		Enzymatic Amidation of Peptides	PENDING	11/5/2002	PEPTIDE	
351	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	JP	2000-581233		DORMADY	5/2/2001		Enzymatic Amidation of Peptides	PENDING		PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
352	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	KR	2000- 7004269		DORMADY			Enzymatic Amidation of Peptides	PENDING	8/12/2001	PEPTIDE	
353	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	MX	PA/a/2001/00 4526		DORMADY	5/4/2001		Enzymatic Amidation of Peptides	PENDING		PEPTIDE	
354	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	NO			DORMADY			Enzymatic Amidation of Peptides	PENDING		PEPTIDE	
355	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	NZ	510791		DORMADY	3/27/2001		Enzymatic Amidation of Peptides	PENDING	7/27/2001	PEPTIDE	
63	60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	PCT	PCT/US99/2 6060		DORMADY	11/5/1999		Enzymatic Amidation of Peptides	PENDING		PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
343	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	RU	2001115715	DORMADY			Enzymatic Amidation of Peptides	PENDING			
344	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	SG	200102439-7	DORMADY	11/5/1999		Enzymatic Amidation of Peptides	PENDING	5/6/2003	PEPTIDE	
345	PCT/US99/26060 11/5/99; 60/107,311 (98/017522) 11/6/98; 09/212,663 (/162) 12/16/98	UA	2001053702	DORMADY	5/31/2001		Enzymatic Amidation of Peptides	PENDING	11/5/2002	PEPTIDE	
162	09/212,663 (/162) 12/16/98; PCT/US99/26060 (/163) 11/5/99; 60/107,311 (98/017522) 11/6/98; PCT/US99/26060 (/163) 11/5/99	US	60/107,311	DORMADY	11/6/1998		Enzymatic Amidation of Peptides	CLOSED			
		US	09/212,663	DORMADY	12/16/1998		Enzymatic Amidation of Peptides	PENDING	7/1/2001	PEPTIDE	





F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
199		US	08/095,162	5512459	WAGNER	7/20/1993	4/30/1996	Enzymatic Method for Modification of Recombinant Polypeptides			BioNebraska
383	CON 08/095,162 7/20/93 (5,512,459)	US	08/470,220	5707826	WAGNER	6/6/1995	1/13/1998	Enzymatic Method for Modification of Recombinant Polypeptides		10/30/2003 PEPTIDE	BioNebraska
106	FWC of 08/520,485 8/29/1995 (aban.); DIV 08/095,162 (5,512,459) and DIV of 08/470,220 (5,707,826)	US	08/967,374 (file jacket also contains 08/520,485)	6037143	WAGNER	11/7/1997	3/14/2000	Enzymatic Method for Modification of Recombinant Polypeptides		7/13/2001 PEPTIDE	BioNebraska
272	CON 08/967,374 (6,037,143); CON 08/520,485 (aban.); DIV 08/470,220 (5,707,826) and 08/095,162 (5,512,459)	US	09/505,991		WAGNER	2/17/2000	Enzymatic Method for Modification of Recombinant Polypeptides			9/14/2003 PEPTIDE	BioNebraska
213	EP 0479897 6/28/90	DE	47987	69032883.4- 08	WAGNER	6/28/1990	1/7/1999	Enzymatically Binding Bioactive Materials to		6/30/2001 PEPTIDE	

F&L NO	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
154		EP	90911128.8 filed 6/29/90	479897 WAGNER	3/30/1999	1/7/1999	Enzymatically Binding Bioactive Materials to Protein	PUBLISHED 8/19/1999		PEPTIDE	
210	EP 0 479 897 6/28/90	FR	90911128.8 filed 6/29/90	479897 WAGNER	6/29/1990	1/7/1999	Enzymatically Binding Bioactive Materials to Protein	GRANTED	6/30/2001	PEPTIDE	
209	EP 0 479 897 6/28/90	GB	90911128.8 filed 6/29/90	479897 WAGNER	6/29/1990	1/7/1999	Enzymatically Binding Bioactive Materials to Protein	PENDING	6/28/2001	PEPTIDE	
180	corresponding to EP 90911128.8 filed 6/29/90 (EP 0 479 897) PCT/US90/03682 filed 6/28/90; 07/375,138 filed 6/30/89	IE	90/2389	81284 WAGNER	6/29/1990	7/24/2000	Enzymatically Binding Bioactive Materials to Protein	PENDING	6/30/2001	PEPTIDE	
380		JP		WAGNER			Enzymatically Binding Bioactive Materials to Protein	ABANDONED		PEPTIDE	
151	PCT/US90/03682	AU		WAGNER	6/28/1990		Enzymatically Binding Bioactive Materials to Proteins	PENDING	6/28/2001	PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DATE	OTHER INFO	ASSIGNEE
377		CA	2063434	WAGNER			Enzymatically Binding Bioactive Materials to Proteins	ABANDONED		PEPTIDE	
150		CH	90911128.8 filed 6/29/90	479897 WAGNER	6/29/1990	1/7/1999	Enzymatically Binding Bioactive Materials to Proteins	PENDING	6/30/2001	PEPTIDE	
153	07/375,138 6/30/89 (5,279,954)	PCT	PCT/US90/0 3682	WAGNER	6/28/1990		Enzymatically Binding Bioactive Materials to Proteins	PENDING		PEPTIDE	
		US	07/375,138	5279954 WAGNER	6/30/1989	1/18/1994	Exopeptidase Catalyzed Site-Specific Bonding of Supports, Labels and Bioactive Agents to Proteins	PATENTED	7/18/2001	PEPTIDE	BioNebraska; Board of Regents of the University of Nebraska
	CON 08/061,913 5/14/93 (aban.); CON 07/375,138 6/30/89 (5,279,954)	US	08/316,810	5741686 WAGNER	10/3/1994	4/21/1998	Exopeptidase Catalyzed Site-Specific Bonding of Supports, Labels and Bioactive Agents to Proteins	PATENTED	10/21/2001	PEPTIDE	Board of Regents of the University of Nebraska

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE	
152	CIP 07/375,138 6/30/89	US	07/545,915	5234820	WAGNER	6/28/1990	8/10/1993	Exopeptidase Catalyzed Site-Specific Bonding of Supports, Labels and Bioactive Agents to Proteins	PATENTE D	2/10/2005	PEPTIDE	BioNebraska; Board of Regents of the University of Nebraska
103							FTO: GLP-1 and Reperfusion	PENDING				
386		PCT	PCT/US01/1 3378		NAUCK	4/26/2001	Gastric Inhibitory Polypeptide Diagnostic Test for Detecting Susceptibility to Type-2 Diabetes, Impaired Glucose Tolerance, or Impaired Fasting Glucose	Priority Info. Due 8/27/01	6/24/2001	ASSAY		
288	09/559,779 (4/27/00)	US	09/559,779		NAUCK	4/27/2000	Gastric Inhibitory Polypeptide Diagnostic Test for Detecting Susceptibility to Type-2 Diabetes, Impaired	PENDING	11/2/2001	ASSAY		

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
289		US	60/	COOLIDG E			Glucose Tolerance, or Impaired Fasting Glucose GLP/Glitazone Combination Therapy for Syndrome X, IGT, and Type II Diabetes (and Type II prevention) GLP-1 and GHRPs in Combination for Treatment of Severe Catabolic Stress Resulting From Recovery From Surgery, Ischemia/Reperfusion, Stroke, Severe Trauma and Injury and Other Acute Stress Conditions	PENDING		MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
371	09/333,415 6/15/99; FOR MONITORING PURPOSES ONLY	PCT	PCT/US00/1 6428	WO 01/00764	HOLST	8/21/2000	1/4/2001 GLP-1 as a Diagnostic Test to Determine Beta-Cell Function and the Presence of the Condition of IGT and Type- II Diabetes	PENDING	7/25/2001	ASSAY	
262		US	09/333,415	HOLST	6/15/1999		GLP-1 as a Diagnostic Test to Determine Beta-Cell Function and the Presence of the Condition of IGT and Type- II Diabetes	PENDING	9/19/2001	ASSAY	
258	FOR MONITORING PURPOSES ONLY	US	60/103,498	COOLIDGE	10/8/1998		GLP-1 Therapy for Myocardial Infarction	EXPIRED; 10/7/99 Coolidge instructed not to convert		CLOSED	MEDICAL
397	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	AU	38899/99	GOKE	12/6/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with	PENDING	7/17/2001	MEDICAL	

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
367	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	BG	105079	GOKE	12/21/2000		Impaired Glucose Tolerance  Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		5/7/2002 MEDICAL		
370	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	BR	PI9911112-8	GOKE	12/11/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		5/7/2002 MEDICAL		

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
392	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	CA	2334872	GOKE	3/20/2001		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		12/11/2001	MEDICAL	
384	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	CU	291/2000	GOKE	12/12/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance			MEDICAL	
335	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	CZ	PV 2000-4614	GOKE	12/8/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance			MEDICAL	



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
393	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	GE	3218/01- 2000	GOKE	12/8/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING	6/26/2001	MEDICAL	
387	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	HU		GOKE	12/12/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING		MEDICAL	
	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	IN		GOKE	12/8/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING		MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
368	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	JP	2000-553129	GOKE	12/12/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance				
336	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	KR	2000- 7014110	GOKE	12/12/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		5/7/2004	MEDICAL	
337	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	MX	12286	GOKE	12/8/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance				

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
381	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	NO	2000 6336	GOKE			Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance				
366	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	SG	200007277-7	GOKE	5/7/1999		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		5/7/2002	MEDICAL	
372	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	SK	PV 1904-2000	GOKE	12/12/2000		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING			MEDICAL

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
399	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	TR	2001/79	GOKE	5/7/1999		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		11/24/2001 MEDICAL		
369	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	UA	2000127165/ M	GOKE			Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance				
261	PCT/US99/10040 5/7/99; 60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	US	60/089,044	GOKE	6/12/1998		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance		5/7/2002 MEDICAL		
	FOR MONITORING PURPOSES ONLY							CLOSED	CLOSED		MEDICAL

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
373	60/089,044 6/12/98; FOR MONITORING PURPOSES ONLY	US	09/719,410	GOKE			Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING	8/14/2001	MEDICAL	
396	PCT/US99/10040 5/7/99; CIP 60/089,044; FOR MONITORING PURPOSES ONLY	UZ	IAP20010024	GOKE	1/12/2001		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING	5/7/2002	MEDICAL	
257	CIP 60/089,044; FOR MONITORING PURPOSES ONLY	WIPO	PCT/US99/1 0040	GOKE	5/7/1999		Glucagon-Like Peptide-1 Improves the Ability of the Beta-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance	PENDING		MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
315	FOR MONITORING PURPOSES ONLY; PCT/US99/05571 filed 3/16/99; WO 99/47161; 60/089,044 6/12/98	US	09/646,433	COOLIDGE E  5614492 and HABENER 5118666	11/24/2000		GRF and GRF+ Testosterone for Broken Hip Habener Patent Infringement Investigation re USP 5,614,492 and 5,118,666 Human Appetite Control by Glucagon-Like Receptor Binding Compounds	PENDING			
255	FOR MONITORING PURPOSES ONLY DIV 93203087.7; USP 859,928 5/5/96	WIPO	PCT/US99/0 5571	GOKE	3/16/1999		Human Appetite Control by Glucagon-Like Receptor Binding Compounds Infringement Investigation of Hoffmann- LaRoche USP 4,728,609 Insulinotropic Hormone	PENDING		MEDICAL	
		EP	87903195.3	HABENER	5/5/1987	8/28/1996					

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
	CIP 08/541,373 10/10/95; CIP 08/462,798 6/5/95	PCT	PCT/US96/0 9258	WYLIE	6/6/1996		Lead Binding Polypeptides and Nucleotides Coding Therefore	CLOSED		ANTIBODY	
		US	08/462,798	WYLIE	6/5/1995		Lead Binding Polypeptides and Nucleotides Coding Therefore	ABANDONED		ANTIBODY	
303	CIP PCT/US96/09258 6/5/96; CON 08/541,773 10/10/95 (aban.); CIP 08/462,798 6/5/96 (aban.)	US	08/767,128	WYLIE	12/4/1996	8/29/2000	Lead Binding Polypeptides and Nucleotides Coding Therefore	PATENTED		ANTIBODY	
		US	08/541,373	WYLIE	10/10/1995		Lead Binding Polypeptides and Nucleotides Coding Therefore	ABANDONED		ANTIBODY	
127		EP	95908736.2	LOPEZ	1/27/1995		Mercury Binding Polypeptides and Nucleotides Coding Therefore	PENDING	1/27/2002	ANTIBODY	
		BE	95908736.2	LOPEZ	1/27/1995	5/26/1999	Mercury Binding Polypeptides and Nucleotides Coding Therefore	GRANTED	1/27/2002	ANTIBODY	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
143		CA	95/00651	2182190	LOPEZ	1/27/1995	Nucleotides Coding Therefore Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding	PENDING	1/27/2002	ANTIBODY	
137		CH	95908736.2	EP0741749	LOPEZ	1/27/1995	5/26/1999 Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding	GRANTED	1/27/2002	ANTIBODY	
139		DE	95908736.2	EP0741749	LOPEZ	1/27/1995	5/26/1999 Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding	GRANTED	1/27/2002	ANTIBODY	
141		FR	95908736.2	EP0741749	LOPEZ	1/27/1995	5/26/1999 Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding	GRANTED	1/27/2002	ANTIBODY	
138		GB	95908736.2	EP0741749	LOPEZ	12/27/1995	5/26/1999 Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding	GRANTED	1/27/2002	ANTIBODY	



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
312		IE	95908736.2	EP0741749B1	LOPEZ	1/27/1995	5/26/1999	Coding Therefore Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding Polypeptides and Nucleotides Coding Therefore Mercury Binding Polypeptides and Nucleotides Coding Therefore	GRANTED	1/27/2002	ANTIBODY
134		PCT	PCT/US95/01199		LOPEZ	1/27/1995					
136	CIP 07/990,542 12/14/92 (5,503,987); CON 07/493,299 3/14/90 (aban.); CIP 07/324,392 3/14/89 (aban.)	US	08/187,407		LOPEZ						
142	CON 08/187,407 1/27/94 (aban.); CIP 07/990,542 12/14/92 (5,503,987); CIP 07/493,299 3/14/90 (aban.); CIP 07/324,392 3/14/89 (aban.)	US	07/888,366	5972656	LOPEZ	7/3/1997	10/26/1999	Mercury Binding Polypeptides and Nucleotides Coding Therefore	ABANDONED		ANTIBODY
142		ZA	95/00651		LOPEZ	1/27/1995		Mercury Binding	PENDING	1/27/2002	ANTIBODY

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
309	09/303,016 4/30/99; CIP 60/103,498 10/8/98 along with 09/302,596; FOR MONITORING PURPOSES ONLY	PCT	PCT/US00/1 1652	COOLIDG E	5/1/2000		Polypeptides and Nucleotides Coding Therefore Metabolic Intervention with GLP-1 or its Biologically Active Analog to Improve the Function of the Ischemic and Reperfused Brain Metabolic Intervention with GLP-1 or its Biologically Active Analog to Improve the Function of the Ischemic and Reperfused Brain Metabolic Intervention with GLP-1 or its Biologically Active Analog to Improve the Function of the Ischemic and Reperfused Brain Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	PENDING	10/30/2001	MEDICAL	
260	CIP 60/103,498 (10/8/98) along with 09/302,596; FOR MONITORING PURPOSES ONLY	US	09/303,016	COOLIDG E	4/30/1999						
310	09/302,596 4/30/99; CIP 60/103,498 along with 09/303,016; FOR MONITORING PURPOSES ONLY	PCT	PCT/US00/1 1251	COOLIDG E	4/27/2000						

F&L NO.	I	F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
113	PCT	259	CIP 60/103,498 (10/8/98) along with 09/303,016; FOR MONITORING PURPOSES ONLY	US	09/302,596	COOLIDGE	4/30/1999		Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	PENDING		MEDICAL	
112	PCT	398	DIV 09/302,596 4/30/99; CIP 60/103,498 (10/8/98) along with 09/303,016; FOR MONITORING PURPOSES ONLY	US		COOLIDGE	5/9/2001		Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfused Tissue	PENDING		MEDICAL	
128	PCT									PENDING		MEDICAL	
131	PCT	111	PCT/US96/13615	AU	69006/96	723383	NAUCK	8/22/1996	12/7/2000 Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	
114	DE	130		CA	2227278		NAUCK	8/22/1996	Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	
132	PCT	129	PCT/US96/13615	CN	96196938.5		NAUCK	8/22/1996	Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2001	MEDICAL	
15	PCT	155	PCT/US96/13615	CZ	PV508-98		NAUCK	8/22/1996	Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2001	MEDICAL	

[2585334/4]

[2585334/4]

F&L NO.	RELATED APPLN. NO.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
259	CIP 60/103,498 (10/8/98) along with 09/303,016; FOR MONITORING PURPOSES ONLY	US	09/302,596		COOLIDGE E	4/30/1999		Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfusion Tissue	PENDING		MEDICAL	
398	DIV 09/302,596 4/30/99; CIP 60/103,498 (10/8/98) along with 09/303,016; FOR MONITORING PURPOSES ONLY	US			COOLIDGE E	5/9/2001		Metabolic Intervention with GLP-1 to Improve the Function of Ischemic and Reperfusion Tissue	PENDING		MEDICAL	
111		AU	69006/96	723383	NAUCK	8/22/1996	12/7/2000	Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	
130		CA	2227278		NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2001	MEDICAL	
129		CN	96196938.5		NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2001	MEDICAL	
155		CZ	PV508-98		NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2001	MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
113	PCT/US96/13615	DE	19530865.4	NAUCK	8/22/1995		Parenteral Nutrition Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/31/2001	MEDICAL	
112	PCT/US96/13615	EP	96929722.5	NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	Bionebraska, Inc.
128	PCT/US96/13615	HU	P9903534	NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	
131	PCT/US96/13615	JP	510445/1997	NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	PENDING	8/22/2003	MEDICAL	
114	DE 19530865.4 8/22/95	PCT	PTC/US96/13615	NAUCK	8/22/1996		Method and Composition for Enhanced Parenteral Nutrition	INACTIVE		MEDICAL	
132	PCT/US96/13615	PL	P-325117	NAUCK	2/20/1998		Method and Composition for Enhanced Parenteral Nutrition	PENDING		MEDICAL	
115	PCT/US96/13615 8/22/96; DE 19530865.4 8/22/95	US	09/011,940	NAUCK	3/3/1999		Method and Composition for Enhanced Parenteral Nutrition	PENDING	6/20/2001	MEDICAL	

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
329	CON 09/011,940 3/3/99; PCT/US96/13615 8/22/96; DE 19530865.4 8/22/95	US	09/749,307	5700775	NAUCK	12/28/2000	12/23/1997	Nutrition  Method and Composition for Enhanced Parenteral Nutrition				
406	8648.76-US-PA	US	08/410,353	5700775	GUTNIAK	3/24/1995	12/23/1997	Method and Treatment Composition for Decreasing Patient Time in Catabolic State After Traumatic Injury Method for Endopeptidase Modification of Proteins Method for Endopeptidase Modification of Proteins	PATENTE D	6/23/2001	MEDICAL	
407		PCT	PCT/US94/08127		WAGNER	7/19/1994		Method for Endopeptidase Modification of Proteins	CLOSED			
408		US	08/094,819		WAGNER	7/20/1993		Method for Endopeptidase Modification of Proteins	ABANDONED			
409	07/912,798 7/13/92	PCT	PCT/US93/06591		GOZZI	7/13/1993		Method for Recombinant Polypeptides	CLOSED			
419		AU	47725/93	673190	STOUT	7/13/1993		Method for Modification of	GRANTED	7/13/2001		PEPTIDE

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
193		CA	2140002	STOUT	7/13/1993		Recombinant Polypeptides Method for Modification of Recombinant Polypeptides	PENDING	7/13/2001	PEPTIDE	
191	PCT/US93/06591 7/13/92; 07/912,793 7/13/92	EP	93918187.1	STOUT	7/13/1993		Method for Modification of Recombinant Polypeptides	PENDING	10/15/2001	PEPTIDE	
385	DIV EP 93918187.1 7/13/93; PCT/US93/06591 7/13/92; 07/912,793 7/13/92	EP	1103311.5	STOUT			Method for Modification of Recombinant Polypeptides	PENDING	7/7/2001	PEPTIDE	
194		JP	6-503577	STOUT	7/13/1993		Method for Modification of Recombinant Polypeptides	PENDING		PEPTIDE	
190		NZ	225041	STOUT	7/13/1993		Method for Modification of Recombinant Polypeptides	PENDING	7/31/2001	PEPTIDE	
	CON 350,709 12/7/94 (aban.); CON 838,857 2/18/92 (aban.)	US	08/835231	NISHIMUR A (Takeda)	4/7/1997	1/19/1999	Method for Producing a Biologically Active Recombinant Cysteine-Free D Parathyroid Hormone (1-34) USP 5,861,284	PENDING			PEPTIDE

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
164		US		WILLIAMS			Methods and DNA Constructs for Increasing Yield of Recombinant Polypeptides Modified Carboxypeptidase	NEW PROVL		PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
211	PCT/IB98/00517	AU	65133/98	MORTENS EN	2/27/1998		Modified Carboxypeptidase	PENDING	8/7/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
220	PCT/IB98/00517; 08/807,263 2/28/97	CA	2281879	MORTENS EN	2/27/1998		Modified Carboxypeptidase	PENDING	2/27/2002	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
225	PCT/IB98/00517	CN	98802877.8	MORTENS EN	2/27/1998		Modified Carboxypeptidase	PENDING	2/27/2002	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
217	PCT/IB98/00517	EP	98910909.5	MORTENS EN	2/27/1998		Modified Carboxypeptidase	PENDING	2/27/2002	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
218	PCT/IB98/00517	JP		MORTENS EN	2/27/1998		Modified Carboxypeptidase	PENDING	2/27/2005	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
316	08/807,263 filed 2/28/97	PCT	PCT/IB98/00517	MORTENS EN	2/27/1998	9/3/1998	Modified Carboxypeptidase	PENDING			Carlsberg Laboratory A/S - 7/92 license
107		US	08/807,263	MORTENS EN	2/28/1997	11/16/1999	Modified Carboxypeptidase	PATENTE D	5/16/2003	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
109	08/807,263 2/28/97 (5,985,627)	US	09/420,785	MORTENS EN	10/19/1999		Modified Carboxypeptid ase	PENDING	12/25/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
165		AU	54114/90	648022 WAGNER	3/14/1990	8/1/1994	Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/14/2002	ANTIBODY	
166		CA	2047717 WAGNER	3/14/1990			Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/14/2002	ANTIBODY	
174		CH	90905954.5 WAGNER	463110 3/14/1990	1/7/1998		Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/31/2002	ANTIBODY	
175	EP 0 463 110 granted 1/7/98	DE	690 31 909.6-08 WAGNER	3/14/1990	1/7/1998		Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/31/2002	ANTIBODY	Board of Regents of the University of Nebraska
167		EP	90905954.4 WAGNER	463110 3/14/1990	1/7/1998		Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/31/2002	ANTIBODY	
173		FI	FI 914298 WAGNER	FI100472 3/14/1990	12/15/1997		Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/31/2002	ANTIBODY	
170		FR	90905954.5 WAGNER	463110 3/14/1990	1/7/1998		Monoclonal Antibodies for Small Moieties Methods Therefor	PENDING	3/31/2002	ANTIBODY	

TRADEMARK

REEL: 002413 FRAME: 0340

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
172		GB	90905954.5	463110	WAGNER	3/14/1990	1/7/1998	Small Moieties Methods Therefor Monoclonal Antibodies for Small Moieties	PENDING	3/14/2002	ANTIBODY
208		IE	922/90	81207	WAGNER	3/14/1990	6/28/2000	Monoclonal Antibodies for Small Moieties	PENDING		ANTIBODY
168	EP 0 463 110 granted 1/7/98	IT	30149/BE/97	463110	WAGNER	3/14/1990	1/7/1998	Monoclonal Antibodies for Small Moieties	PENDING	3/31/2002	ANTIBODY
171		JP	505840/1990		WAGNER	3/14/1990		Small Moieties Methods Therefor Monoclonal Antibodies for Small Moieties	PENDING	3/31/2002	ANTIBODY
169		NL	90905954.5	463110	WAGNER	3/14/1990	1/7/1998	Methods Therefor Monoclonal Antibodies for Small Moieties	PENDING		ANTIBODY
404	07/324,392 3/14/89	PCT	US90/01401		WAGNER	3/14/1990		Small Moieties Methods Therefor Monoclonal Antibodies for Small Moieties	PENDING	3/31/2002	ANTIBODY

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
297	CON 07/493,299 3/14/90 (aban.); CIP 07/324,392 3/14/89 (aban.)	US	07/990,543 5503987	WAGNER	12/14/1992	4/2/1996	Monoclonal Antibodies Specific for Small Moieties D and Methods Therefor	PATENTE	10/2/2003	ANTIBODY	Board of Regents of the University of Nebraska
321	CON 07/990,542 12/14/92; CON 07/493,299 3/14/90 (aban.); CIP 07/324,392 3/14/89 (aban.)	US	08/266,163 5639624	WAGNER	6/27/1994	6/17/1997	Monoclonal Antibodies Specific for Small Moieties D and Methods Therefor	PATENTE	12/17/2004	ANTIBODY	BioNebraska; Board of Regents of the University of Nebraska
229	CON 08/266,163 6/27/94 (5,639,624); CON 07/990,542 12/14/92 (aban.); CON 07/493,299 3/14/90 (aban.); CIP of 07/324,392 3/14/89 (aban.)	US	08/773,688 5807695	WAGNER	12/27/1996	9/15/1998	Monoclonal Antibodies Specific for Small Moieties and Methods Therefor	PATENTE	3/15/2002	ANTIBODY	Board of Regents of the University of Nebraska
204	EP 9492064.6	AT	94920064.6 E 184108; 0706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING	6/30/2001	ANTIBODY	
	PCT/US94/06200	AU	7098194 675724	CARLSON	6/2/1994		Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	GRANTED		ANTIBODY	

TRADEMARK

REEL: 002413 FRAME: 0342

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
198	PCT/US94/06200 6/2/94	CA	2165970	CARLSON	6/2/1994		Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING		ANTIBODY	
234		CH	706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PATENTE D	6/30/2001	ANTIBODY	
233	EP 9492064.6	DE	706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING	6/30/2001	ANTIBODY	
212	EP 9492064.6	EP	9492064.6	CARLSON	6/2/1994	9/1/1999	Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING	6/30/2001	ANTIBODY	
232		FR	706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	GRANTED	6/30/2001	ANTIBODY	
231	EP 9492064.6	GB	706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING	6/30/2001	ANTIBODY	
	EP 9492064.6						Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING		ANTIBODY	

TRADEMARK

REEL: 002413 FRAME: 0343

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
230	EP 9492064.6	IT	706655	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING	6/30/2001	ANTIBODY	
197		JP	502846/1995	CARLSON	6/2/1994		Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PENDING		ANTIBODY	
376		PCT	PCT/US94/06200	CARLSON			Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	ABANDONED		ANTIBODY	
228		US	08/096,671	CARLSON	6/22/1993	7/2/1996	Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PATENTE D	1/2/2004	ANTIBODY	BioNebraska
304		US	08/469,489	CARLSON	6/6/1995	4/15/1997	Monoclonal Antibody Assay and Kit for Detecting Metal Cations in Body Fluids	PATENTE D			
338	CON 08/096,671 6/22/93 (5,532,136)  60/181,934 2/11/00	AU		CONLON			Novel Antimicrobial Peptides	PENDING	10/15/2004	MEDICAL	Creighton University School of Medicine

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
339	60/181,934 2/11/00	CA		CONLON			Novel Antimicrobial Peptides	PENDING		MEDICAL	Creighton University School of Medicine
341	60/181,934 2/11/00	EP		CONLON			Novel Antimicrobial Peptides	PENDING		MEDICAL	Creighton University School of Medicine
340	60/181,934 2/11/00	JP		CONLON			Novel Antimicrobial Peptides	PENDING		MEDICAL	Creighton University School of Medicine
235		US	60/181,934	CONLON	2/11/2000		Novel Antimicrobial Peptides	PENDING		MEDICAL	Creighton University School of Medicine
196		US		COOLIDG E, EHLERS			Organ Preservation and Islet Cell Transplantation with GLP1 Paladium- Catalyzed Peptide Cleavage	NEW PROV'L		MEDICAL	Creighton University School of Medicine
306		US		HOLMQUI ST			Patentability of Cyanalation Technology Peptide Pharmaceutic al Formulations	NEW PROV'L		PEPTIDE	
390	60/205,262 5/19/01; 60/205,377 5/17/00	PCT	PCT/US01/1 5872	HOLMQUI ST	5/17/2001			PENDING	7/25/2001	MEDICAL	

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
388	60/205,262 5/19/01; 60/205,377 5/17/00	US	09/858,880	HOLMQUI ST	5/17/2001		Peptide Pharmaceutic al Formulations	PENDING	10/20/2001	MEDICAL	
302	89187/195	US	60/205,262	HOLMQUI ST	5/19/2000		Peptide Pharmaceutic al Formulations	PENDING		MEDICAL	
195	89187/302	US	60/205,377	HOLMQUI ST, DORMADY	5/17/2000		Pharmaceutial Formulations of GLP-1, PTH & GFR	PENDING		MEDICAL	
		US	60/				Polypeptides with Proserin Related Activity	PENDING			
				COOLIDG E			Pretreatment of Stroke with GLP1	NEW PROV'L		MEDICAL	
273		US	06/136,661	JOHANSE N	4/2/1980	7/13/1982	Process for Enzymatic Production of Peptides	PATENTE D		PEPTIDE	De Forenede Bryggerier A/S - LICENSED?
		AT	548217	BUCHARD T	548217		Process for the Preparation of C-Terninally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
177	EP0548217	AU	660944	BUCHARD T	9/13/1991		Process for the Preparation of C-Terninally Amidated Peptides	PATENTE D	9/13/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
274	EP0548217	BE	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
178		CA	2092721	BUCHARD T	9/13/1991		Process for the Preparation of C-Terminally Amidated Peptides	8/22/01 ltr to clt re OA resp. due 08/09/01 FA ltr enclosing Office Action, resp. due 10/10/01;			Carlsberg Laboratory A/S - 7/92 license
275	EP 0 548217; PCT/DK91/00268 9/14/90	CH	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
276	EP0548217	DE	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
277	EP0548217	DK	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
179		EP	91916824.5	548217	BUCHARD T	9/13/1991	4/9/1997	Process for the Preparation of C-Terminally Amidated Peptides	GRANTED	9/13/2011 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
278	EP0548217	ES	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
279	EP0548217	FR	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
280	EP0548217	GB	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/13/2001 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
409		IE	3255/91	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/7/2001 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
284	EP0548217	IT	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001 PEPTIDE	Carlsberg Laboratory A/S - 7/92 license

TRADEMARK

REEL: 002413 FRAME: 0348

F&L NO.	RELATED APPLN. NO.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
176	PCT/DK91/00268 9/14/90	JP	515220/91		BUCHARD T	9/13/1991		Process for the Preparation of C-Terminally Amidated Peptides	PENDING	12/18/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
283	EP0548217	LU	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
282	EP0548217	NL	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
281	EP0548217	SE	548217	548217	BUCHARD T			Process for the Preparation of C-Terminally Amidated Peptides	PENDING	9/30/2001	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
301	CON 08/039,306 4/15/93 (aban.)	US	08/431,539	5580751	BUCHARD T	4/21/1995	12/3/1996	Process for the Preparation of C-Terminally Amidated Peptides	PENDING	6/3/2004	PEPTIDE	Carlsberg Laboratory A/S - 7/92 license
	08/350,528 12/7/94 (aban.)	PCT	PCT/US95/1 5799		STOUT	7/12/1995		Production of C-Terminal Amidated Peptides From ED Recombinant Protein	ABANDON		PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY	APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
135	08/350,528 12/7/94 (aban.)	US	08/934,171	6051399	STOUT	9/13/1997	4/18/2000	Production of C-Terminal Amidated Peptides From Recombinant Protein Constructs Production of C-Terminal Amidated Peptides From Recombinant Protein Constructs	PATENTE	10/18/2003	PEPTIDE	
215	CON 08/934,171 9/13/97;	US			STOUT			Amidated Peptides From Recombinant Protein Constructs	ABANDON ED		PEPTIDE	
116		AU	44158/96	700605	PARTRIDGE	12/7/1995		Production of Peptides Using Recombinant Fusion Protein Constructs	PENDING	12/7/2001	PEPTIDE	
118		CA	2206848		PARTRIDGE	12/7/1995		Production of Peptides Using Recombinant Fusion Protein Constructs	PENDING	12/7/2002	PEPTIDE	
119		EP	95942995.2		PARTRIDGE	12/7/1995		Production of Peptides Using Recombinant Fusion Protein Constructs	PENDING	12/31/2001	PEPTIDE	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
120		JP	517724/1996	PARTRIDG E	12/7/1995		Production of Peptides Using Recombinant Fusion Protein Constructs	PENDING	12/7/2002	PEPTIDE	
117		PCT	PCT/US95/15800	PARTRIDG E	12/7/1995		Production of Peptides Using Recombinant Fusion Protein Constructs	INACTIVE		PEPTIDE	
110	CON 08/905,631 8/4/97;	US		PARTRIDG E			Production of Peptides Using Recombinant Fusion Protein Constructs	PENDING		PEPTIDE	
311	CON 08/680,004 7/15/96 (aban.); DIV 07/552,810 7/16/90 (5,595,887)	US	6127150	COOLIDG E	9/5/1997	10/3/2000	Purification of Peptides	PENDING		PEPTIDE	BioNebraska
271	EP 92902529	AT	92902529.4	COOLIDG E			Purification Directed Cloning of Peptides	PENDING	6/30/2001	PEPTIDE	
124		CA	2087261	COOLIDG E	6/24/1991		Purification Directed Cloning of Peptides	PENDING	7/2/2001	PEPTIDE	

TRADEMARK

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
265	EP 92902529	CH	92902529.4	539530 COOLIDG E			Peptides Purification Directed Cloning of Peptides	PENDING	6/30/2001	PEPTIDE	
268	EP 92902529	DE	691 31 961.8-08	539530 COOLIDG E			Purification Directed Cloning of Peptides	PENDING	6/30/2001	PEPTIDE	
266	EP 92902529	DK	92902529.4	DK/EP 0539530 COOLIDG E			Purification directed cloning of peptides	PUBLISHE D	6/30/2001	PEPTIDE	
123		EP	92902529.4	539530 COOLIDG E	6/24/1991	2/2/2000	Purification Directed Cloning of Peptides	GRANTED		PEPTIDE	
269	EP 92902529	FR	92902529.4	539530 COOLIDG E			Purification Directed Cloning of Peptides	PENDING	6/30/2001	PEPTIDE	
270	EP 92902529	GB	92902529.4	539530 COOLIDG E			Purification Directed Cloning of Peptides	PENDING	6/24/2001	PEPTIDE	
313	PCT/US91/04511	IE	2464/91	COOLIDG E			Purification Directed Cloning of Peptides	PENDING		PEPTIDE	
267	EP 92902529	IT	67532/BE/20 00	539530 COOLIDG E			Purification Directed Cloning of Peptides	PENDING	6/30/2001	PEPTIDE	
122		JP	500610/1992	3129437 COOLIDG E	6/24/1991	11/17/2000	Purification Directed Cloning of Peptides	PENDING	11/17/2003	PEPTIDE	

[2585334 4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
126		NZ	238812	COOLIDG E	6/24/1991		Cloning of Peptides Purification Directed Cloning of Peptides	GRANTED		PEPTIDE	
	07/522,810 7/16/90 (5,595,887)	PCT	PCT/US91/0 4511	COOLIDG E	6/24/1991		Purification Directed Cloning of Peptides	PENDING			
	07/522,810 7/16/91 (5,595,887)	PCT	PCT/US91/0 4511	COOLIDG E	6/24/1991		Purification Directed Cloning of Peptides	CLOSED			
264	EP 92902529	SE	539530	COOLIDG E			Purification directed cloning of peptides	PENDING	6/30/2001	PEPTIDE	
308	CON 08/927,128 9/5/97; CON 08/680,004 7/15/96 (aban.); DIV 07/552,810 7/16/90 USP 5,595,887	US	09/597,734	COOLIDG E	6/19/2000		Purification Directed Cloning of Peptides	PENDING			Bionebraska
125		ZA	91/5307	COOLIDG E	6/24/1991		Purification Directed Cloning of Peptides	PENDING		PEPTIDE	
296		US	07/552,810	COOLIDG E	7/16/1990	1/21/1997	Purification Directed Cloning of Peptides Using Carbonic	PATENTE D	7/21/2004	PEPTIDE	BioNebraska

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
214	PCT/US97/01652	AU	22545/97	710695	WAGNER	2/4/1997	Anhydrase as the Affinity Binding Segment Recombinant Preparation of Calcitonin Fragments and Use Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PENDING	2/4/2002 PEPTIDE		
148		CA	2245681		WAGNER	2/4/1997	Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PENDING	2/4/2002 PEPTIDE		
149	PCT/US97/01652	CN	97193123.2		WAGNER	2/4/1997	Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PENDING	2/4/2002 PEPTIDE		
147		EP			WAGNER		Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PENDING	2/28/2002 PEPTIDE		
146		JP	528594/97		WAGNER	2/4/1997	Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PENDING	2/4/2002 PEPTIDE		

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
145		US	08/595,868 5962270	WAGNER	2/6/1996	10/5/1999	and Use Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PATENTE D	4/5/2003	PEPTIDE	BioNebraska
144		US	09/139,819 6,251,635	WAGNER	8/25/1998	6/26/2001	Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PATENTE D	12/26/2004	PEPTIDE	BioNebraska
328	DIV 08/595,868 2/6/96 (5,962,270)	US	09/750,913	WAGNER	1/2/2001		Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	PATENTE D			BioNebraska Inc. 1/2/01 011443/0790
	DIV 09/139,819 8/25/98; DIV 08/595,868 2/6/96 (5,962,270)	WO	PCT/US97/0 1652	WAGNER	2/4/1997		Thereof in the Preparations Recombinant Preparation of Calcitonin Fragments and Use	CLOSED		PEPTIDE	
	08/595,868 2/6/96 (5,962,270)						Thereof in the Preparations Review of Issue with Lonza	PENDING			



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE	
	CIP 07/288,009 12/21/88 (5,049,656)	US	07/454,372	5221736	COOLIDG E	12/21/1989	6/22/1993	Sequential Oligonucleotid e Synthesis Using Affinity Techniques	PATENTE D	12/12/2004	PEPTIDE	BioNebraska; Board of Regents of the University of Nebraska
	DIV 07/454,372 12/21/89 (5,221,736); CIP 07/288,009 12/21/88 (5,049,656)	US	08/018,100	5464759	COOLIDG E	2/17/1993	11/7/1995	Sequential Oligonucleotid e Synthesis Using Immunoaffinity Techniques	PATENTE D	5/7/2003	PEPTIDE	BioNebraska; Board of Regents of the University of Nebraska
226		AU	48494/90	645964	LEWIS	12/21/1989	Sequential Peptide and Oligonucleotid e Synthesis Using Immunoaffinity Techniques	GRANTED			PEPTIDE	
205	PCT/US95/06682	DK	1203/91	LEWIS	12/21/1989		Sequential Peptide and Oligonucleotid e Synthesis Using Immunoaffinity Techniques	PENDING			PEPTIDE	
		US	07/288,009	5049656	LEWIS	12/21/1988	9/17/1991	Sequential Peptide and Oligonucleotid e Synthesis Using Immunoaffinity Techniques	PATENTE D	3/17/2003	PEPTIDE	
		PCT	US89/05737			12/21/1989	Sequential Peptide and Oligonucleotid	CLOSED				

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
254		NZ	240482	RECKER	11/5/1991	10/13/1997	e Synthesis Using Immunoaffinity Techniques Somatostatin "Reduction" and Aging Stanford-Cohen License Agreement The Use of Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH) for the Manufacture of Medicaments for Treating Osteoporosis Therapeutic Methods using GLP1 and GRF	PENDING			
263	07/617,543 11/26/90 ABAN	US	4870054	RECKER	7/31/1987	9/26/1989	TM Clearance for BioN Treatment for Osteoporosis Using GRF or	PENDING	11/5/2001	MEDICAL	
292		60/		COOLIDGE							
		US	07/080,110	RECKER	7/31/1987	9/26/1989	TM Clearance for BioN Treatment for Osteoporosis Using GRF or	PENDING			

[2583334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
239	EP0559751	AT	AT E 150 648 T1	599751 RECKER	11/1/1991	3/26/1997	a Biologically Active Analog Thereof Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
242	07/617,543 11/26/90 ABAN	AU	90735/91	645874 RECKER	11/1/1991	5/16/1994	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	PATENTE D	11/1/2001	MEDICAL	
240	07/617,543 11/26/90 ABAN	BE	599751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
241		CA	2,096.35	RECKER	11/1/1991		Parathyroid Hormone (PTH)  Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	PENDING	11/1/2001	MEDICAL	
	PCT/US91/08106										
251		CH	92900612	559751	RECKER	11/1/1991	3/26/1997 Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
248		DE	69125394	559751	RECKER	11/1/1991	3/26/1997 Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
	07/617,543 11/26/90 ABAN										

TRADEMARK

REEL: 002413 FRAME: 0359

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
238		DK	DK/EP 559751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	PATENTE D	11/1/2001	MEDICAL	
	07/617,543 11/26/90 ABAN										
		EP	92900612 559751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	CLOSED			
		ES	92900612 559751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
	07/617,543 11/26/90 ABAN										

253

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
237		FI	932385	106776	RECKER	11/1/1991	4/12/2001 Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	PENDING	11/30/2001	MEDICAL	
249	PCT/US91/08106; 07/617,543 11/26/90 ABAN	FR	92900612	559751	RECKER	11/1/1991	3/26/1997 Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
250	EP 0559751	GB	92900612	559751	RECKER	11/1/1991	3/26/1997 Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	

TRADEMARK

REEL: 002413 FRAME: 0361

[2585334/4]

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
247	07/617,543 11/26/90 ABAN	IE	3858/91	RECKER	11/5/1991		with Parathyroid Hormone (PTH) Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	PENDING			
246	07/617,543 11/26/90 ABAN	IT	15900	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
245	07/617,543 11/26/90 ABAN	JP	501851/92	RECKER	11/1/1991	9/5/1996	with Parathyroid Hormone (PTH) Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination	GRANTED	9/5/2001	MEDICAL	

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
244	07/617,543 11/26/90 ABAN	LU	559751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
243	07/617,543 11/26/90 ABAN	NL	559751	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	
152	07/617,543 11/26/90 ABAN	SE	92900612	RECKER	11/1/1991	3/26/1997	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)	GRANTED	11/1/2001	MEDICAL	

TRADEMARK



F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
236		US	07/787,051	5164368	RECKER	11/4/1991	11/17/1992	Treatment for Osteoporosis Using Growth Hormone Releasing Factor (GRF) in Combination with Parathyroid Hormone (PTH)			
	CON 07/617,543 11/26/90 ABAN							PATENTE D			MEDICAL
394		US	06/780,949	4710382	RECKER	9/27/1985	12/1/1987	Treatment for Osteoporosis Using HGRF(1-40)NH2			
	60/205,239 5/19/00	PCT	PCT/US01/1 5996	COOLIDG E, EHLERS	5/18/2001		Treatment of Acute Coronary Syndrome with GLP1	PATENTE D			MEDICAL
263		US	60/205,239	COOLIDG E, EHLERS	5/19/2000		Treatment of Acute Coronary Syndrome with GLP1	PENDING	7/19/2001		MEDICAL
395		US	60/205,239 5/19/00	COOLIDG E, EHLERS	5/18/2001		Treatment of Acute Coronary Syndrome with GLP1	PENDING			MEDICAL

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
305		US	60/	COOLIDG E			Treatment of Alzheimer's Disease with GRF				
293				EHLERS			Treatment of Asthma with GLP1				
317		US	60/245,234	COOLIDG E	11/3/2000		Treatment of Breast Cancer with GLP1	NEW PROV'L			
				COOLIDG E			Treatment of Burns with GLP1	NEW PROV'L		MEDICAL	
		US	60/245,234	COOLIDG E, EHLERS			Treatment of Hibernating Myocardium and Diabetic Cardiomyopathy with a GLP-1 Peptide	Pending		MEDICAL	
364		US	60/242,139	COOLIDG E, EHLERS	10/23/2000		Treatment of Hibernating Myocardium with GLP-1	PENDING	7/23/2001	MEDICAL	
391		US	60/285,699	HOLST	4/24/2001		Treatment with GLP-1 to Improve Blood Glucose, Insulin Sensitivity and Beta-Cell Function	PENDING	10/24/2001		
							US Patent Search re Process for Chelate	PENDING			

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
121		AU	662301	COOLIDGE			Binding of Fusion Proteins				
222		GB	TM				US Patent Search re				
411	PCT/US99/26060, 11/4/99; 09/212,663, 12/16/98; 60/107,311, 11/6/98	HK	99956920.5	DORMADY			Process for Production of Insoluble Fusion Proteins	PENDING	6/24/2001		
412		US	60/322,430	CONLON	9/17/2001		ENZYMATIC AMIDATION OF PEPTIDES	To be filed		Related to 89187-356	
414		US	09/982,978	COOLIDGE	10/22/2001		ANTIMICROBIAL PEPTIDES FROM P. PARADOXA TREATMENT OF HIBERNATING MYOCARDIUM AND	PENDING			

F&L NO.	RELATED APPLN.	COUNTRY APPLN. NO.	PATENT NO.	INVENTOR	FILED	ISSUE	TITLE/ SUBJECT	STATUS	NEXT ACTION DUE DATE	OTHER INFO	ASSIGNEE
							DIABETIC CARDIOMYO PATHY WITH A GLP-1 PEPTIDE				

## SCHEDULE 2

### Restoragen Trademarks

1. Bimelyze (registered)
2. Betatropin (filed and suspended by the Patent & Trademark Office). Another company has filed with the Patent & Trademark Office to use this mark. Unless we can reach an agreement with the company, we will not get this mark.
3. Restoragen (filed)
4. Macro Pharmaceuticals (filed)
5. Macro Pharma (filed)